Don't get left behind! The modernized is coming. Check it out now.
Say goodbye to!
The new site is coming soon - go to the modernized
Working… Menu

Special Combination of OBP-301 and Pembrolizumab

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03172819
Recruitment Status : Completed
First Posted : June 1, 2017
Last Update Posted : September 28, 2022
Oncolys BioPharma Inc
Merck Sharp & Dohme LLC
Information provided by (Responsible Party):
Toshihiko Doi, National Cancer Center Hospital East

Brief Summary:
This is multicenter, open-label Phase I study to exploratively evaluate the efficacy and safety of OBP-301 in combination with Pembrolizumab in patients with advanced solid tumors.

Condition or disease Intervention/treatment Phase
Advanced Solid Tumor Biological: OBP-301 Drug: Pembrolizumab Phase 1

Detailed Description:

Phase 1a part:

To evaluate safety and tolerability in combination of OBP-301 and Pembrolizumab in patient with advanced or metastatic solid tumor and to determine recommended dose in phase 1b part.

Phase 1b part:

To evaluate safety and potential efficacy in combination of OBP-301 and Pembrolizumab in patients in expanded arm.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 22 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open Label Phase I Study to Evaluate the Safety and Efficacy of OBP-301 With Pembrolizumab in Patients With Advanced Solid Tumors
Actual Study Start Date : October 1, 2017
Actual Primary Completion Date : April 6, 2021
Actual Study Completion Date : April 6, 2022

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: OBP-301+Pembrolizumab
Biological: OBP-301

Intratumoral injection directly into the dose target region of a tumor at Day 1, Day 15, and Day 29.

Additional administration of OBP-301 After the recommended dose of OBP-301 has been established, additional administration of OBP-301 is allowed. After completion of administration of OBP-301 on Day 1 - Day 29(+/- 4 days), if the target region has not disappeared, additional administration of OBP-301 is allowed after Day 43 or later.

The patients in Phase 1a, Pembrolizumab administration has continued, are included.

The recommended dose determined in the Phase 1a part will be administered 3 times biweekly (+/- 4 days); max 4 cycles.

Drug: Pembrolizumab
200 mg Pembrolizumab is infused intravenously at Day 8. Thereafter infusion will continue every 3 weeks until discontinuation.

Primary Outcome Measures :
  1. Dose limiting toxicity (DLT) [ Time Frame: 4weeks ]
    Dose limiting toxicity

Secondary Outcome Measures :
  1. Response rate (RR) [ Time Frame: 3 years ]
    Response rate by RECIST ver. 1.1

  2. Progression free survival (PFS) [ Time Frame: 3 years ]
    Progression free survival

  3. Rate of adverse event [ Time Frame: 3 years ]
    Rate of adverse event

Other Outcome Measures:
  1. Biomarkers:Efficacy evaluations according to immune status [ Time Frame: 3 years ]
    Immune status will be analyzed using biopsy and blood samples by flow cytometry, RNA seq, whole exome sequencing, and immunohistochemistry, etc.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria

  1. Be willing and able to provide written informed consent/assent for the trial.
  2. Be >=18 years of age on the day of signing the informed consent.
  3. Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  4. Have histologically or cytologically confirmed advanced or metastatic solid tumor with possibility of intratumoral injection, for which no effective standard therapy exists or standard therapy has failed.
  5. Have one or more evaluable lesions based on RECIST 1.1

    *Evaluable lesions: measurable lesion and/or non-measurable lesion

  6. Be willing to provide tissue; newly obtained endoscopic biopsy specimens or formalin-fixed, paraffin-embedded (FFPE) block specimens.
  7. Female subjects of childbearing potential have a negative urine or serum pregnancy test within 7 days prior to enrollment. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required. It is allowed that the test at the same day at 7 days prior to enrollment. And male / female subjects of childbearing potential must be agree to use an adequate method of contraception starting with signing the informed consent through 120 days after the last dose of study medication.
  8. Demonstrated adequate organ function as defined in following criteria. All screening labs should be performed within 7 days of enrollment. It is allowed that the labs at the same day at 7days prior to enrollment.

Note: Subject must not have taken transfusion, hematopoietic agent; granulocyte-colony stimulating factor (G-CSF) etc., and/or oxygen inhalation within 7 days before the screening labs.

  1. Absolute neutrophil count (ANC)>=1,500 /mm3
  2. Platelets>=100,000 /mm3
  3. Hemoglobin>=9.0 g/dL
  4. Serum total bilirubin<=2.0 mg/dL
  5. aspartate aminotransferase (AST) (SGOT) and alanine aminotransferase (ALT) (SGPT)<=100 IU/L for subjects with liver metastases<=200 IU/L
  6. Serum creatinine<= 1.5 mg/dL; or if serum creatinine > 1.5 mg/dL, creatinine/clearance >=60 mL/min (Cockcroft-Gault formula)

Exclusion criteria

  1. Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy within 4 weeks of study Day 1.
  2. Has an active autoimmune disease that has required systemic treatment in past 2 years.
  3. Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to study Day 1.
  4. Has known active central nervous system metastases and/or carcinomatous meningitis.
  5. Has had prior anti-cancer monoclonal antibody chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study Day 1 or immunotherapy targeted to Programmed cell death 1 (PD-1), PD-L1, PD-L2 within 4 weeks prior to Da y 1 or OBP-301 study, who has not recovered from adverse events due to a previously administered agent.
  6. Has a known additional malignancy that is progressing or requires active treatment.
  7. Has received a live vaccine within 30 days of planned start of study therapy.
  8. Has a known history of Human Immunodeficiency Virus.
  9. Has known active Hepatitis B or Hepatitis C.
  10. Has known history of, or any evidence of active, non-infectious pneumonitis.
  11. Has an active infection requiring systemic therapy.
  12. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
  13. Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the screening visit through 120 days after the last dose of trial treatment.
  14. Previous severe hypersensitivity to another monoclonal antibody
  15. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03172819

Layout table for location information
National Cancer Center Hospital East
Kashiwa, Chiba, Japan
Sponsors and Collaborators
Toshihiko Doi
Oncolys BioPharma Inc
Merck Sharp & Dohme LLC
Layout table for investigator information
Study Chair: Toshihiko Doi, Dr National Cancer Center Hospital East
Layout table for additonal information
Responsible Party: Toshihiko Doi, Chief / Division of experimental therapeutics, National Cancer Center Hospital East Identifier: NCT03172819    
Other Study ID Numbers: EPOC1505
First Posted: June 1, 2017    Key Record Dates
Last Update Posted: September 28, 2022
Last Verified: September 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Antineoplastic Agents, Immunological
Antineoplastic Agents
Immune Checkpoint Inhibitors
Molecular Mechanisms of Pharmacological Action